Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2008

Vermillion and Johns Hopkins Continue on Quest to Develop Cancer Diagnostics

  • Vermillion renewed a long-standing collaboration with Johns Hopkins University for the development of novel cancer biomarkers. Vermillion will have exclusive access to commercial rights related to the discoveries made through the partnership.

    The collaborators expect to apply them to disease detection, classification, and monitoring of cancers including ovarian, breast, and prostate.

    Vermillion will continue to provide financial support, technical assistance, and access to its technologies. Johns Hopkins will contribute cancer serum samples and the clinical and scientific expertise.

    “For more than seven years we have had a highly productive relationship with Daniel W. Chan, professor of pathology/urology/oncology/radiology and his esteemed team at Johns Hopkins University,” points out Eric Fung, M.D., Ph.D., CSO of Vermillion. “This collaboration has led to the development of our ovarian tumor triage test, and we look forward to expanding this steadfast relationship.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »